Lv65
2250 积分 2021-12-01 加入
Lazertinib in EGFR-Variant Non–Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors
2个月前
已完结
The Role of Lazertinib in Patients With EGFR-Variant Non–Small Cell Lung Cancer
2个月前
已完结
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis
2个月前
已完结
Impact of PD-L1 expression on the efficacy of first-line crizotinib in advanced ROS1-rearranged NSCLC
3个月前
已完结
Rhabdomyosarcomatous Transformation as a Mechanism of Resistance to Osimertinib and Savolitinib in EGFR-Mutant Lung Adenocarcinoma With METamp After Osimertinib First-Line Treatment
3个月前
已完结
Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial
3个月前
已完结
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial
4个月前
已完结
ALK-positive lung cancer: a moving target
5个月前
已完结
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
6个月前
已完结
Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer
6个月前
已完结
皖公网安备34019202002308
